VEGFA and renal cell carcinoma: RCC treatment has developed significantly, as vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors and drugs that inhibit mammalian target of rapamycin (mTOR) signaling have become the mainstay for the management of advanced RCC.